Probiotic Use in Gastrointestinal Conditions

Introduction to Probiotics

Probiotics have specific, strain-dependent efficacy for certain gastrointestinal conditions, but are not universally beneficial across all GI disorders 1, 2

The American Gastroenterological Association recommends specific probiotic strains for targeted gastrointestinal conditions, including Saccharomyces boulardii, 2-strain combination: Lactobacillus acidophilus CL1285 and L. casei LBC80R, 3-strain combination: L. acidophilus, L. delbrueckii subsp bulgaricus, and Bifidobacterium bifidum, and 4-strain combination: L. acidophilus, L. delbrueckii subsp bulgaricus, B. bifidum, and Streptococcus salivarius subsp thermophilus, based on conditional recommendation and low quality evidence 3, 1
An 8-strain combination (VSL#3) containing L. paracasei subsp paracasei, L. plantarum, L. acidophilus, L. delbrueckii subsp bulgaricus, B. longum subsp longum, B. breve, B. longum subsp infantis, and S. salivarius subsp thermophilus is recommended for certain conditions, based on conditional recommendation and very low quality evidence 3, 1
For infants <37 weeks gestational age, recommended strains include B. animalis subsp lactis, L. reuteri, and L. rhamnosus, based on conditional recommendation and low quality evidence 3

The American Gastroenterological Association suggests against using probiotics for children with acute infectious gastroenteritis, based on conditional recommendation and moderate quality evidence 3
Probiotics are not recommended for reducing duration or severity of diarrhea, with moderate evidence quality and two large North American trials showing no benefit 1, 2
There is insufficient evidence for induction or maintenance of remission, with low evidence quality and a significant knowledge gap 1, 2
There is no definitive recommendation for probiotic use in certain conditions due to a knowledge gap, with some individual strains showing benefit in single trials but no strain or combination studied with sufficient rigor 1, 2

Probiotics are generally safe in most populations, but caution is advised in immunocompromised patients, critically ill patients, and preterm infants due to the risk of contamination 2

Current evidence for probiotics has significant limitations, including inconsistent reporting of adverse events, lack of product manufacturing details, variable quality of studies, and insufficient strain-specific analyses 3, 4, 5
Probiotic effects are species- and strain-specific, and benefits cannot be extrapolated across all probiotics 2

The American Gastroenterological Association guidelines will undergo review within 3-5 years as new evidence emerges 3
The field of probiotics research continues to evolve, with many knowledge gaps still existing, and future high-quality studies may change these recommendations as our understanding of specific strain efficacy improves 2